DermTech Announces New Website

Dec 02, 2015, 06:00 ET from DermTech, Inc.

SAN DIEGO, Dec. 2, 2015 /PRNewswire/ -- Today, DermTech, Inc., a privately held commercial stage molecular diagnostic company developing gene expression tests for skin cancer, announced the release of its new website (, designed to provide education and information to both physicians and patients about DermTech's platform technology and first product, the Pigmented Lesion Assay (PLA) and non-invasive adhesive skin biopsy used to aid in the diagnosis of melanoma. DermTech is the first to offer gene expression tests directly to the physician to aid in diagnosis with specimens collected using an adhesive patch, rather than a scalpel.

"We are excited to introduce this new website which accurately reflects the high tech, innovative nature of our company and highlights the benefits of non-invasively obtained gene expression data to both the physician and concerned patients. The website details the benefits of our non-invasive adhesive biopsy and PLA test in aiding in the detection of melanoma, as well DermTech's unique platform technology that can be used as a stand alone diagnostic or diagnostic aid, or to support clinical drug development. This new website will further support the expansion of our commercial activities," said Sarah Dennison, Vice President of Marketing.

ABOUT DermTech

DermTech is a commercial stage molecular dermatology company developing non-invasive gene expression tests to aid the clinical diagnosis of skin cancer and other skin conditions.  DermTech operates a CLIA licensed laboratory located in the company's La Jolla, CA headquarters. DermTech's technology allows the analysis of skin biopsy samples collected non-invasively using an adhesive patch. DermTech provides highly accurate, objective information to physicians to improve care and reduce costs. Current dermatologic diagnosis is primarily based on subjective visual pattern recognition that is prone to error and results in a substantial number of unnecessary surgical procedures.  For additional information visit:

Media Contact:
Sarah Dennison, MBA
VP of Marketing
(858) 450-4222


SOURCE DermTech, Inc.